Isomorphic signs up Lilly, Novartis for $3bn AI drug hunt
pharmaphorum
JANUARY 8, 2024
Alphabet’s AI in drug discovery startup Isomorphic Labs signs collaborations with Eli Lilly and Novartis worth up to $3bn, its first two pharma partnerships
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
pharmaphorum
JANUARY 8, 2024
Alphabet’s AI in drug discovery startup Isomorphic Labs signs collaborations with Eli Lilly and Novartis worth up to $3bn, its first two pharma partnerships
pharmaphorum
OCTOBER 17, 2023
Owkin signs up another pharma partner for its AI platform Phil.Taylor Tue, 17/10/2023 - 10:29 Bookmark this
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
SEPTEMBER 11, 2023
After plotting a course to grow by leveraging its biosimilar expertise, Sandoz has inked a deal to get involved in one of the industry's next major biosim debuts. | The blockbuster inflammatory med's patents begin to expire this year, leaving biosimilar makers scrambling for a piece of the large market.
Fierce Pharma
JANUARY 10, 2023
Celltrion signs up to support Rani’s oral biosimilar copy of J&J’s Stelara, lands right of first negotiation. Tue, 01/10/2023 - 10:24.
Fierce Pharma
APRIL 25, 2024
Even as new Sanofi drugs like Beyfortus and Altuviiio come into their own, the French pharma’s immunology powerhouse Dupixent shows no signs of slowing down. Even as new Sanofi drugs like Beyfortus and Altuviiio come into their own, the French pharma’s immunology powerhouse Dupixent shows no signs of slowing down.
Pharmaceutical Technology
JANUARY 23, 2024
Genentech will utilise GenEdit’s non-viral polymer nanoparticles for gene therapy delivery in autoimmune diseases.
Pharmaceutical Technology
APRIL 6, 2023
US-based biotechnology company ImmunoGen has signed a term loan financing facility worth up to $175m with the entities of Pharmakon Advisors. ImmunoGen will use the proceeds from the agreement to support its growth trajectory and bolster its balance sheet. The company will receive the loan facility in two tranches.
Pharmaceutical Technology
AUGUST 25, 2022
Sonoma Biotherapeutics has signed a lease agreement for setting up an 83,000ft² research and development (R&D) and manufacturing centre for cell therapies. The post Sonoma signs deal to set up manufacturing centre for cell therapies appeared first on Pharmaceutical Technology.
MedCity News
FEBRUARY 15, 2024
The event will take place in Chicago at the Ritz Carlton from May 21-22. The startup tracks include: oncology, cardiology, women’s health and preventing burnout/supporting operational efficiency. The deadline to submit applications is February 29 so apply today!
Fierce Pharma
OCTOBER 4, 2023
The Federal Trade Commission (FTC) recently came up short in its attempt to derai | More than 30 companies and biopharma associations have introduced the Partnership for the US Life Science Ecosystem (PULSE) to increase awareness of the value of M&A. AbbVie, Gilead, Merck and Novartis also are in the fold.
Pharmaceutical Technology
OCTOBER 20, 2023
Daiichi Sankyo will receive an upfront payment of $4bn and will be eligible for additional milestone payments of up to $22bn.
Fierce Pharma
AUGUST 24, 2023
Royalty Pharma has signed a deal with Ferring Pharmaceuticals to collect royalties on bladder cancer drug Adstiladrin. Royalty will pay $300 million up front and $200 million in a potential milestone tied to Ferring meeting certain manufacturing goals. New York City-based Royalty will receive 5.1%
Fierce Pharma
JUNE 22, 2023
The United Nations-backed Medicines Patent Pool signed up four generic drugmakers to produce copycats of Novartis’ myeloid leukemia blockbuster Tasigna. More than a year ago, eight pharma giants partnered to | A partnership among pharma giants to provide cancer medicines to some poorer nations just took a major step toward fruition.
Storyvine
JULY 14, 2021
At Storyvine we've dramatically simplified the onboarding filming process to get your storymakers started more quickly and easily. When it's time to activate your people to film, simply send them a QR code. It will take them right where they need to go to register and download their template.
pharmaphorum
FEBRUARY 27, 2024
Novo Nordisk has signed a wide-ranging deal with US molecular glue biotech Neomorph that could be worth up to $1.46
MedCity News
NOVEMBER 16, 2023
Knowing that many tech solutions end up being not as effective as health systems would have hoped, two health system executives gave examples of tools they believe have made a significant impact on staffing issues at their organizations.
European Pharmaceutical Review
MARCH 31, 2023
The Medicines Patent Pool (MPP) has signed sublicence agreements with three generics manufacturers to produce generic versions of cabotegravir long-acting (LA) injectable for human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP). The pharma companies who will manufacture the generic versions are Viatris, Aurobindo and Cipla.
MedCity News
MARCH 9, 2023
Last week, New Mexico-based Presbyterian Healthcare Services and Midwest-based UnityPoint Health signed a letter of intent to merge.
European Pharmaceutical Review
JULY 6, 2023
BioNTech SE and the UK government have jointly agreed to provide up to 10,000 patients with personalised cancer immunotherapies by 2030. Signing of this agreement builds on a memorandum of understanding signed in January. Could BioNTech’s new partnership accelerate personalised mRNA therapy trials?
MedCity News
SEPTEMBER 13, 2022
The biotech will still need to show that the drug’s efficacy can hold up in a pivotal study, but the results so far are a positive sign for the NASH field, which has been marred by clinical trial failures. Akero Therapeutics’ experimental NASH drug, efruxifermin, met the main and secondary goals of Phase 2b clinical trial.
Pharmaceutical Technology
NOVEMBER 28, 2022
C4X Discovery (C4XD) and AstraZeneca have entered an exclusive global licensing agreement worth up to $402m to develop oral therapy to treat inflammatory and respiratory ailments. The deal has been signed to develop the C4X NRF2 Activator programme for these ailments. This includes an upfront payment of $2m from AstraZeneca.
World of DTC Marketing
JULY 26, 2022
Patients who sign up on their own are charged an annual fee of $199 for a suite of services, including on-demand video health consultations available at all hours and other benefits. ” At its core is an app and website that members can use to book appointments, track health records and renew prescriptions.
Copyright Clearance Center
APRIL 11, 2023
CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, today announced it has signed a bilateral agreement with the Malaysia Reprographic Rights Centre (MARC) to support its operations and the development of copyright-compliant content consumption in Malaysia benefitting both rightsholders and content users.
World of DTC Marketing
APRIL 13, 2021
Most doctors sign on in the morning and see a snapshot of what’s happening by their specialty. 2wo: Up To Date – Up to Date has 54 doctors on staff and more than 430 journals hand-searched and reviewed. Here are some options. 1ne: Medscape – Still number one with physicians.
Impetus Digital
FEBRUARY 1, 2024
Sign up anyway and we will follow up with you directly! Register for this exclusive webinar Can’t make one of the live webinars?
European Pharmaceutical Review
APRIL 5, 2024
For people with [propionic acidaemia], harmful amounts of toxic metabolites can build up in the body and lead to metabolic decompensation events and multisystemic complications.
Pharmaceutical Technology
MAY 11, 2023
Half of these patients experienced a rise in neoantigen-specific T cells which persisted for up to two years. At an 18-month follow-up, those who received the treatment were reported to have a longer recurrence-free survival, and the authors concluded that the T cell responses correlated with delayed disease recurrence.
Medgadget
JULY 14, 2023
Spotting the signs of fever early could make a difference in providing early treatment or beginning a period of isolation to reduce the chance of disease transmission. Running a fever is a common early sign of COVID-19 and many other viral diseases. This is particularly important for viral diseases, such as COVID-19.
pharmaphorum
AUGUST 2, 2022
Sosei Heptares has signed up a string of big pharma collaborators over the last few years, and one of them – AbbVie – has just expanded its partnership with a new to deal to apply the biotech’s G protein-coupled receptor (GPCR) expertise to the discovery of drugs for neurological diseases.
Impetus Digital
JANUARY 30, 2023
Sign up now! Register for this free webinar If you can’t make the date, don’t worry – sign up anyway and we’ll send you a link to the recording after the webinar.
Pharmaceutical Technology
DECEMBER 19, 2022
Innate is also eligible to receive a total of up to $1.43bn (€1.35bn) in preclinical, clinical, regulatory and commercial milestone payments and royalty payments on net sales in the future. As per the deal, Sanofi will hold an option to include up to two further ANKET targets.
World of DTC Marketing
MAY 30, 2021
Google has signed an agreement with the Mayo clinic to help analyze data as they want a slice of healthcare dollars but what’s missing from these tech companies is “the human touch” that patients want. SUMMARY: Amazon has set its sights on healthcare as it smells another profit opportunity.
European Pharmaceutical Review
MARCH 13, 2023
Sandoz has signed a Memorandum of Understanding (MOU) to build a new biologics production plant in Lendava, Slovenia. The company’s expected $400 million investment is the largest-ever international private-sector investment in the country. biosimilars are] projected to grow double-digit annually over the next decade.”
Impetus Digital
APRIL 22, 2024
Sign up anyway and we will follow up with you directly! Can’t make one of the live webinars?
Pharmaceutical Technology
NOVEMBER 29, 2022
AstraZeneca has signed an agreement for the acquisition of all outstanding equity of clinical-stage biotechnology firm Neogene Therapeutics in a deal totalling up to $320m. Under the deal, Neogene will receive $200m in initial payment at closing, as well as up to $120m in contingent milestones-based and non-contingent payments.
Pharmaceutical Technology
OCTOBER 19, 2022
Eli Lilly and Company has signed a definitive agreement for the acquisition of all outstanding shares of precision genetic medicine firm Akouos for a total deal value of up to nearly $610m or up to $15.50 for each share in cash. The deal comprises an acquisition value of $12.50 The deal comprises an acquisition value of $12.50
Pharmaceutical Technology
FEBRUARY 14, 2023
Cullinan Oncology has signed an exclusive licence with Harbour BioMed for clinical-stage B7H4 x 4-1BB bispecific immune activator HBM7008’s (CLN-418) development and marketing in the US. The post Cullinan Oncology signs licence deal with Harbour BioMed appeared first on Pharmaceutical Technology.
Pharmaceutical Technology
AUGUST 1, 2022
The contract comprises a $1.74bn award to produce and supply these vaccine doses and options to further procure up to 234 million additional doses of the company’s booster candidates. The post Moderna signs contract to supply Covid-19 booster vaccines to the US appeared first on Pharmaceutical Technology.
Medical Device Success
OCTOBER 3, 2021
We talk about disruptive technologies, early adopters, key opinion leaders, signs you are approaching the chasm, the pragmatists on the other side of the chasm, pragmatists in pain, the bowling alley, the tornado, mistakes to avoid and much much more. I always set up interviews as live virtual events so members can attend.
Legacy MEDSearch
JANUARY 20, 2023
Also, make sure you follow any companies you are interested in on LinkedIn and sign up for Google notifications for job titles you are interested in! Instead of signing on for your 9-5 role, picture you are signing on to work for yourself. What new certifications have you picked up in recent years?
pharmaphorum
JULY 5, 2022
AstraZeneca has signed a deal to buy US biotech TeneoTwo in a deal worth up to $1.27 The big pharma is paying $100 million upfront for the company, and offering up to $805 million in milestone payments if TeneoTwo’s drug candidates meet development objectives, plus up to $360 million if they hit sales targets.
MedReps
OCTOBER 11, 2022
Nurses seemingly have a leg up when it comes to branching into medical sales. Sign up for those classes and learn everything you can about the subjects. Walking up to a salesperson you don’t know and badgering them with questions when they’re busy is not the best method to gain knowledge. They more than likely will.
Impetus Digital
JUNE 17, 2022
When people sign up with us, we have a very stringent process of checking different things like IP addresses and making sure that their conditions match the medications that they’ve recorded. When people sign up through that link, we will donate money back to that organization. That’s a pretty good way.
Pharmaceutical Technology
NOVEMBER 16, 2022
Each year at the annual UN climate summits, many businesses set up pavilions at the event and have high-level meetings with policymakers. For some, this is a worrying sign of corporate capture. Many businesses have made net-zero commitments ; living up to those means being present and advocating for climate ambition, she argues. "It
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content